Not understanding your reference...
As it stands today the only employees noted in this company is CEO and lawyer, neither of which are diabetes experts.
Presumably the Diabetes Relief acquisition would be related as well as their phase 3 clinical drug Liprostin to treat PAD, however there is no communication here to indicate either of these items are yet in progress. Bigger and Better diabetes treatments and care management are being developed and worked on by the industry weekly.
This company languishes behind an idle, outdated website and un important corporate maneuvers and commentary. Trades about a few thousand bucks worth daily while stagnant quo erodes potential they may have. Silence sets precedent which is not conducive to developing long term supporters.
IMO
News 
Market Data 
Discover 
